<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015287</url>
  </required_header>
  <id_info>
    <org_study_id>12918</org_study_id>
    <secondary_id>H7T-MC-TADF</secondary_id>
    <nct_id>NCT01015287</nct_id>
  </id_info>
  <brief_title>A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction</brief_title>
  <acronym>ACCOAST</acronym>
  <official_title>A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the potential benefits/risks regarding
      pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants
      with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention
      (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial consists of two arms. One arm is a non pre-treatment arm. Participants in this arm
      will receive placebo immediately after NSTEMI diagnosis and prior to the diagnostic coronary
      angiography. A 60 mg prasugrel loading dose will be given immediately after coronary
      angiography when proceeding to PCI. Subsequently, participants will receive daily maintenance
      doses of prasugrel until day 30. Participants who are greater than or equal to 75 years of
      age or who have a body weight less than 60 kilograms (kg) will receive 5 mg oral dose daily.
      All others will receive a 10 mg oral daily maintenance dose for 30 days.

      The other arm is a pre-treatment arm where participants will receive a split loading dose
      regimen with 30 mg of prasugrel administered immediately after NSTEMI diagnosis and prior to
      diagnostic coronary angiography. The remainder of the loading dose (30 mg) will be
      administered when the participants are proceeding to PCI. Subsequently, participants will
      receive daily maintenance doses of prasugrel until day 30. Participants who are greater than
      or equal to 75 years of age or who have a body weight less than 60 kg will receive 5 mg oral
      dose daily. All others will receive a 10 mg oral daily maintenance dose for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP) IIb/IIIa Inhibitor Bailout</measure>
    <time_frame>First loading dose (LD) through 7 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing a CV death, MI, stroke, UR or GPIIb/IIIa Inhibitor bailout divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-Cause Death, Myocardial Infarction (MI), Stroke, or All Coronary Artery Bypass Graft (CABG) and Non-CABG Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</measure>
    <time_frame>First loading dose (LD) through 7 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing an all-cause death, MI, stroke or CABG and non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke Through 30 Days From First Loading Dose (LD)</measure>
    <time_frame>First LD through 30 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing a CV death, MI, or stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of Cardiovascular (CV) Death or Myocardial Infarction (MI) Through 30 Days From First Loading Dose (LD)</measure>
    <time_frame>First LD through 30 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing a CV death or MI divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Urgent Revascularization (UR) Through 30 Days From First Loading Dose (LD)</measure>
    <time_frame>First LD through 30 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing a CV death, MI, or UR divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of Cardiovascular (CV) Death Through 30 Days From First Loading Dose (LD)</measure>
    <time_frame>First LD through 30 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing a CV death divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of Definite or Probable Stent Thrombosis (ST) According to the Academic Research Consortium (ARC) Criteria Through 30 Days From First Loading Dose (LD)</measure>
    <time_frame>First LD through 30 days after first LD</time_frame>
    <description>ARC criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least one of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. The percentage of participants is the total number of participants experiencing a definite or probable stent thrombosis divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-cause Death, Myocardial Infarction (MI), Stroke, or All Coronary Artery Bypass Graft (CABG) and Non-CABG Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Through 30 Days From First Loading Dose (LD)</measure>
    <time_frame>First LD through 30 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing an all-cause death, MI, stroke or CABG and non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Standardized Troponin From Baseline to Percutaneous Coronary Intervention (PCI)</measure>
    <time_frame>Baseline, before PCI (not greater than 48 hours after randomization)</time_frame>
    <description>Standardized troponin is defined as the ratio of the assayed troponin value divided by the upper limit of normal (ULN). Least Squares (LS) means were obtained from an Analysis of Covariance (ANCOVA) model with treatment as a fixed effect and baseline standardized troponin as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of All Coronary Artery Bypass Graft (CABG) or Non-CABG Thrombolysis In Myocardial Infarction (TIMI) Major Bleeding</measure>
    <time_frame>First loading dose (LD) through 7 days after first LD</time_frame>
    <description>The percentage of participants is the total number of participants experiencing a CABG or non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Summary of All-Cause Death</measure>
    <time_frame>Randomization through 30 days</time_frame>
    <description>All deaths, regardless of possible relatedness, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4033</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Non pre-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Split Loading Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered once orally</description>
    <arm_group_label>Non pre-treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Non pre-treatment</arm_group_label>
    <arm_group_label>Split Loading Dose</arm_group_label>
    <other_name>LY640315</other_name>
    <other_name>Efient</other_name>
    <other_name>Effient</other_name>
    <other_name>CS-747</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have acute coronary syndrome consisting of non-ST-segment elevation with elevated
             troponin

          -  Scheduled for coronary angiography/PCI greater than or equal to 2 and less than 24
             hours from time of planned randomization, but no more than 48 hours from randomization

          -  Must be eligible for treatment with prasugrel, aspirin (ASA), and a glycoprotein
             IIb/IIIa receptor (GPIIb/IIIa) inhibitor as per respective labels

          -  May be on a maintenance dose of clopidogrel 75 mg and must be able to switch to
             prasugrel

          -  Must be enrolled at a cardiac catheterization laboratory hospital or at a
             hospital/ambulance service affiliated with a cardiac catheterization laboratory
             hospital

        Exclusion Criteria:

          -  Present with ST-segment elevation myocardial infarction (STEMI) at the time of entry
             or randomization

          -  Have cardiogenic shock

          -  Have refractory ventricular arrhythmias

          -  Have New York Heart Association (NYHA) Class IV congestive heart failure (CHF)

          -  Have had cardiac arrest within 1 week of entry or randomization into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Braunau Am Inn</city>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>A1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>Vancouver</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plzen</city>
        <zip>30460</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>169 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Usti Nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bastia</city>
        <zip>20600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Caluire Et Cuire</city>
        <zip>69300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cannes Cedex</city>
        <zip>06401</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chateauroux</city>
        <zip>36019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lagny Sur Marne</city>
        <zip>77405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metz Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montauban</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreuil</city>
        <zip>93105</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pau Cedex</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienne</city>
        <zip>38209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dachau</city>
        <zip>85221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eutin</city>
        <zip>23701</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rastatt</city>
        <zip>76437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beer Yaakov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tiberias</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Legnano</city>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lucca</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Massa</city>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Napoli</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prato</city>
        <zip>50047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venezia</city>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liepaja</city>
        <zip>3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klaipedos</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tiel</city>
        <zip>4002 WP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belchatow</city>
        <zip>97-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chrzanow</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klodzko</city>
        <zip>57-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mielec</city>
        <zip>39-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naleczow</city>
        <zip>24-140</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nowy Sacz</city>
        <zip>33-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nowy Targ</city>
        <zip>34-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nysa</city>
        <zip>48-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Polanica-Zdroj</city>
        <zip>57-320</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Radom</city>
        <zip>26-617</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sanok</city>
        <zip>38-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Starogard Gdanski</city>
        <zip>82-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-114</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carnaxide</city>
        <zip>2794-006</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Adana</city>
        <zip>1330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fatih</city>
        <zip>34300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Isparta</city>
        <zip>32100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kocaeli</city>
        <zip>41900</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sisli</city>
        <zip>34381</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <results_first_submitted>January 17, 2014</results_first_submitted>
  <results_first_submitted_qc>January 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>P2Y12</keyword>
  <keyword>NSTEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non Pre-treatment</title>
          <description>A placebo oral loading dose (LD) was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
        </group>
        <group group_id="P2">
          <title>Pre-treatment</title>
          <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1996"/>
                <participants group_id="P2" count="2037"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1996"/>
                <participants group_id="P2" count="2037"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1924"/>
                <participants group_id="P2" count="1958"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria not Met</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Non Pre-treatment</title>
          <description>A placebo oral loading dose (LD) was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
        </group>
        <group group_id="B2">
          <title>Pre-treatment</title>
          <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1996"/>
            <count group_id="B2" value="2037"/>
            <count group_id="B3" value="4033"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.59" spread="11.239"/>
                    <measurement group_id="B2" value="63.80" spread="11.270"/>
                    <measurement group_id="B3" value="63.69" spread="11.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="558"/>
                    <measurement group_id="B2" value="552"/>
                    <measurement group_id="B3" value="1110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1438"/>
                    <measurement group_id="B2" value="1485"/>
                    <measurement group_id="B3" value="2923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP) IIb/IIIa Inhibitor Bailout</title>
        <description>The percentage of participants is the total number of participants experiencing a CV death, MI, stroke, UR or GPIIb/IIIa Inhibitor bailout divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First loading dose (LD) through 7 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP) IIb/IIIa Inhibitor Bailout</title>
          <description>The percentage of participants is the total number of participants experiencing a CV death, MI, stroke, UR or GPIIb/IIIa Inhibitor bailout divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.77"/>
                    <measurement group_id="O2" value="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All-Cause Death, Myocardial Infarction (MI), Stroke, or All Coronary Artery Bypass Graft (CABG) and Non-CABG Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</title>
        <description>The percentage of participants is the total number of participants experiencing an all-cause death, MI, stroke or CABG and non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First loading dose (LD) through 7 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-Cause Death, Myocardial Infarction (MI), Stroke, or All Coronary Artery Bypass Graft (CABG) and Non-CABG Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</title>
          <description>The percentage of participants is the total number of participants experiencing an all-cause death, MI, stroke or CABG and non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57"/>
                    <measurement group_id="O2" value="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke Through 30 Days From First Loading Dose (LD)</title>
        <description>The percentage of participants is the total number of participants experiencing a CV death, MI, or stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First LD through 30 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke Through 30 Days From First Loading Dose (LD)</title>
          <description>The percentage of participants is the total number of participants experiencing a CV death, MI, or stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21"/>
                    <measurement group_id="O2" value="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death or Myocardial Infarction (MI) Through 30 Days From First Loading Dose (LD)</title>
        <description>The percentage of participants is the total number of participants experiencing a CV death or MI divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First LD through 30 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death or Myocardial Infarction (MI) Through 30 Days From First Loading Dose (LD)</title>
          <description>The percentage of participants is the total number of participants experiencing a CV death or MI divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.51"/>
                    <measurement group_id="O2" value="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Urgent Revascularization (UR) Through 30 Days From First Loading Dose (LD)</title>
        <description>The percentage of participants is the total number of participants experiencing a CV death, MI, or UR divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First LD through 30 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Urgent Revascularization (UR) Through 30 Days From First Loading Dose (LD)</title>
          <description>The percentage of participants is the total number of participants experiencing a CV death, MI, or UR divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31"/>
                    <measurement group_id="O2" value="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death Through 30 Days From First Loading Dose (LD)</title>
        <description>The percentage of participants is the total number of participants experiencing a CV death divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First LD through 30 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of Cardiovascular (CV) Death Through 30 Days From First Loading Dose (LD)</title>
          <description>The percentage of participants is the total number of participants experiencing a CV death divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10"/>
                    <measurement group_id="O2" value="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of Definite or Probable Stent Thrombosis (ST) According to the Academic Research Consortium (ARC) Criteria Through 30 Days From First Loading Dose (LD)</title>
        <description>ARC criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least one of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. The percentage of participants is the total number of participants experiencing a definite or probable stent thrombosis divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First LD through 30 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of Definite or Probable Stent Thrombosis (ST) According to the Academic Research Consortium (ARC) Criteria Through 30 Days From First Loading Dose (LD)</title>
          <description>ARC criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least one of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. The percentage of participants is the total number of participants experiencing a definite or probable stent thrombosis divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All-cause Death, Myocardial Infarction (MI), Stroke, or All Coronary Artery Bypass Graft (CABG) and Non-CABG Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Through 30 Days From First Loading Dose (LD)</title>
        <description>The percentage of participants is the total number of participants experiencing an all-cause death, MI, stroke or CABG and non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First LD through 30 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-cause Death, Myocardial Infarction (MI), Stroke, or All Coronary Artery Bypass Graft (CABG) and Non-CABG Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Through 30 Days From First Loading Dose (LD)</title>
          <description>The percentage of participants is the total number of participants experiencing an all-cause death, MI, stroke or CABG and non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.52"/>
                    <measurement group_id="O2" value="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Standardized Troponin From Baseline to Percutaneous Coronary Intervention (PCI)</title>
        <description>Standardized troponin is defined as the ratio of the assayed troponin value divided by the upper limit of normal (ULN). Least Squares (LS) means were obtained from an Analysis of Covariance (ANCOVA) model with treatment as a fixed effect and baseline standardized troponin as a covariate.</description>
        <time_frame>Baseline, before PCI (not greater than 48 hours after randomization)</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had standardized troponin measured at baseline and before PCI (not greater than 48 hours after randomization).</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral loading dose (LD) was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Standardized Troponin From Baseline to Percutaneous Coronary Intervention (PCI)</title>
          <description>Standardized troponin is defined as the ratio of the assayed troponin value divided by the upper limit of normal (ULN). Least Squares (LS) means were obtained from an Analysis of Covariance (ANCOVA) model with treatment as a fixed effect and baseline standardized troponin as a covariate.</description>
          <population>All randomized participants who received at least 1 dose of study drug, had standardized troponin measured at baseline and before PCI (not greater than 48 hours after randomization).</population>
          <units>ratio of assayed troponin/ULN</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="454"/>
                <count group_id="O2" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.24" spread="8.93"/>
                    <measurement group_id="O2" value="2.82" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of All Coronary Artery Bypass Graft (CABG) or Non-CABG Thrombolysis In Myocardial Infarction (TIMI) Major Bleeding</title>
        <description>The percentage of participants is the total number of participants experiencing a CABG or non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
        <time_frame>First loading dose (LD) through 7 days after first LD</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral LD was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of All Coronary Artery Bypass Graft (CABG) or Non-CABG Thrombolysis In Myocardial Infarction (TIMI) Major Bleeding</title>
          <description>The percentage of participants is the total number of participants experiencing a CABG or non-CABG TIMI major bleeding divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35"/>
                    <measurement group_id="O2" value="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of All-Cause Death</title>
        <description>All deaths, regardless of possible relatedness, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table.</description>
        <time_frame>Randomization through 30 days</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Pre-treatment</title>
            <description>A placebo oral loading dose (LD) was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Pre-treatment</title>
            <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of All-Cause Death</title>
          <description>All deaths, regardless of possible relatedness, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1996"/>
                <count group_id="O2" value="2037"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiogenic Shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During or Immediately Following a CABG Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During or Immediately Following a PCI Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sudden Cardiac Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intracranial Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke, non-hemorrhagic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Cardiac Hemorrhage, Not Intracranial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non Pre-treatment</title>
          <description>A placebo oral loading dose (LD) was given at the time of diagnosis and a 60 milligrams (mg) oral LD of prasugrel was given at the time of percutaneous coronary intervention (PCI) followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
        </group>
        <group group_id="E2">
          <title>Pre-treatment</title>
          <description>A 30 mg oral LD of prasugrel was given at diagnosis and a 30 mg oral dose of prasugrel was given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="1996"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperchromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary no-reflow phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary ostial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhage coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peritoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1996"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Puncture site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vena cava injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac output decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Inflammatory marker increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Troponin t increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute generalised exanthematous pustulosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="860" subjects_at_risk="1996"/>
                <counts group_id="E2" subjects_affected="876" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="1996"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="1996"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="1996"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="1996"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary no-reflow phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1996"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocardial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="50" subjects_affected="49" subjects_at_risk="1996"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gene mutation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Right aortic arch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Type v hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Refraction disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1996"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="1996"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Mesenteric haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="1996"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1996"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Catheter site phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="56" subjects_affected="55" subjects_at_risk="1996"/>
                <counts group_id="E2" events="50" subjects_affected="47" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1996"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Puncture site discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="1996"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1996"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to chemicals</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Iodine allergy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Eye abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatitis e</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Leprosy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1996"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dislocation of sternum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Post procedural oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Antibiotic resistant staphylococcus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic bruit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood bilirubin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase mb increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood urine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Carbohydrate tolerance decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="1996"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Central venous pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Electrocardiogram st segment depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Electrocardiogram st segment elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Electrophoresis protein abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1996"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hepatitis c virus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Inflammatory marker increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral pulse decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Troponin i increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="1996"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="1996"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="1996"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="1996"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypo hdl cholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1996"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lipid metabolism disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Overweight</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1996"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bone swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1996"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1996"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1996"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="1996"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1996"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Histrionic personality disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Libido disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Transient psychosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemoglobinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1996"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Strangury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
              </event>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Prostatic calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Testicular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1485"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Bronchostenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1996"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="1996"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="1996"/>
                <counts group_id="E2" events="48" subjects_affected="38" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pharyngeal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1996"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1996"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Xanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder catheter removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood product transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Carotid angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Heart valve operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Packed red blood cell transfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1996"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Platelet transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thromboembolectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="62" subjects_affected="57" subjects_at_risk="1996"/>
                <counts group_id="E2" events="97" subjects_affected="96" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1996"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="88" subjects_affected="88" subjects_at_risk="1996"/>
                <counts group_id="E2" events="90" subjects_affected="90" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="1996"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Macroangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Reperfusion injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1996"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1996"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Varicose vein ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1996"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1996"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2037"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1996"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2037"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

